Melatonin in cancer management: Progress and promise

Cancer Research

Volumn 66, Issue 20, 2006, Pages 9789-9793

  Jung, Brittney ^a   Ahmad, Nihal ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALMODULIN; CISPLATIN; CYCLIC AMP; ETOPOSIDE; G PROTEIN COUPLED RECEPTOR; MELATONIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TAMOXIFEN;

ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER; CANCER INHIBITION; CANCER MODEL; CANCER SUSCEPTIBILITY; CHEMOTHERAPY; CLINICAL TRIAL; DNA DAMAGE; DRUG ACTIVITY; DRUG POTENTIATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; GENETIC TRANSCRIPTION; HORMONE ACTION; HUMAN; NEOPLASM; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; MELATONIN; NEOPLASMS;

EID: 33750557481     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1776     Document Type: Review

References (32)

1. Carlberg C. Gene regulation by melatonin. Ann N Y Acad Sci 2000;917:387-96.
2. Melatonin. Monograph. Altern Med Rev 2005;10:326-36.
3. Vijayalaxmi, Thomas CR, Jr., Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002;20:2575-601.
4. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9:11-24.
5. Nosjean O, Nicolas JP, Klupsch F, Delagrange P, Canet E, Boutin JA. Comparative pharmacological studies of melatonin receptors: MT1, MT2, and MT3/QR2. Tissue distribution of MT3/QR2. Biochem Pharmacol 2001;61:1369-79.
6. Dietz BM, Kang YH, Liu G, et al. Xanthohumol isolated from Humulus lupulus inhibits menadione-induced DNA damage through induction of quinone reductase. Chem Res Toxicol 2005;18:1296-305.
7. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002;2:113-32.
8. Cohen M, Lippman M, Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet 1978;2:814-6.
9. Mills E, Wu P, Seely D, Guyatt G. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005;39-360-6.
10. Lee CO. Complementary and alternative medicines patients are talking about: melatonin. Clin J Oncol Nurs 2006;10:105-7.
11. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 2005;27:179-88.
12. Martin V, Herrera F, Carrera-Gonzalez P, et al. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 2006;66:1081-8.
13. Stevens RG. Electric power use and breast cancer: a hypothesis. Am J Epidemiol 1987;125:556-61.
14. Sanchez-Barcelo EJ, Cos S, Fernandez R, Mediavilla MD. Melatonin and mammary cancer: a short review. Endocr Relat Cancer 2003;10:153-9.
15. Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995;71:854-6.
16. Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 1990;11:578-610.
17. Lissoni P, Barni S, Ardizzoia A, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 1992;49:336-9.
18. Lissoni P, Meregalli S, Fossati V, et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 1994;80:464-7.
19. Slominski A, Fischer TW, Zmijewski MA, et al. On the role of melatonin in skin physiology and pathology. Endocrine 2005;27:137-48.
20. Gonzalez R, Sanchez A, Ferguson JA, et al. Melatonin therapy of advanced human malignant melanoma. Melanoma Res 1991;1:237-43.
21. Bangha E, Elsner P, Kistler GS. Suppression of UV-induced erythema by topical treatment with melatonin (N-acetyl-5-methoxytryptamine). A dose response study. Arch Dermatol Res 1996;288:522-6.
22. Neri B, Fiorelli C, Moroni F, et al. Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study. Cancer 1994;73:3015-9.
23. Lissoni P, Barni S, Ardizzoia A, Tancini G, Conti A, Maestroni G. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 1994;73:699-701.
24. Lissoni P. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Ann N Y Acad Sci 2000; 917:560-7.
25. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001;93:1557-62.
26. Davis S, Mirick DK. Circadian disruption, shift work, and the risk of cancer: a summary of the evidence and studies in Seattle. Cancer Causes Control 2006;17:539-45.
27. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 2001;93:1563-8.
28. Grin W, Grunberger W. A significant correlation between melatonin deficiency and endometrial cancer. Gynecol Obstet Invest 1998;45:62-5.
29. Schernhammer ES, Laden F, Speizer FE, et al. Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 2003;95:825-8.
30. Panzer A, Viljoen M. The validity of melatonin as an oncostatic agent. J Pineal Res 1997;22:184-202.
31. Lissoni P, Barni S, Mandala M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999;35:1688-92.
32. Miller SC, Pandi PS, Esquifino AI, Cardinali DP, Maestroni GJ. The role of melatonin in immunoenhancement: potential application in cancer. Int J Exp Pathol 2006;87:81-7.